Molecular Templates (MTEM) versus Affimed (NASDAQ:AFMD) Critical Comparison

Molecular Templates (NASDAQ: MTEM) and Affimed (NASDAQ:AFMD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, dividends, profitability, institutional ownership, risk, analyst recommendations and valuation.


This table compares Molecular Templates and Affimed’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Molecular Templates N/A -56.65% -47.31%
Affimed -1,074.37% -72.94% -57.13%

Institutional & Insider Ownership

16.2% of Molecular Templates shares are held by institutional investors. Comparatively, 31.0% of Affimed shares are held by institutional investors. 13.0% of Molecular Templates shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Earnings & Valuation

This table compares Molecular Templates and Affimed’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Molecular Templates $76.92 million 3.31 -$24.09 million ($1.72) -5.50
Affimed $6.88 million 17.96 -$35.65 million ($0.78) -2.82

Molecular Templates has higher revenue and earnings than Affimed. Molecular Templates is trading at a lower price-to-earnings ratio than Affimed, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Molecular Templates has a beta of 3.08, meaning that its share price is 208% more volatile than the S&P 500. Comparatively, Affimed has a beta of 2.25, meaning that its share price is 125% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and target prices for Molecular Templates and Affimed, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Molecular Templates 0 1 1 0 2.50
Affimed 0 2 1 0 2.33

Molecular Templates presently has a consensus target price of $5.20, suggesting a potential downside of 45.03%. Affimed has a consensus target price of $6.50, suggesting a potential upside of 195.45%. Given Affimed’s higher probable upside, analysts plainly believe Affimed is more favorable than Molecular Templates.


Molecular Templates beats Affimed on 8 of the 12 factors compared between the two stocks.

About Molecular Templates

Molecular Templates, Inc., formerly Threshold Pharmaceuticals, Inc., is a clinical-stage biotechnology company. The Company is engaged in the discovery and development of therapeutic and diagnostic agents that selectively target tumor cells for the treatment of patients living with cancer. The Company also focused on the discovery, development, and commercialization of immunotoxins called engineered toxin bodies (ETBs). The Company is developing two therapeutic product candidates based on hypoxia-activated prodrug technology: evofosfamide and tarloxotinib. The Company’s lead drug candidate MT-3724 is an is an immunotoxin that targets the CD20 cell surface antigen present in a variety of lymphomas and leukemias.

About Affimed

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells. Its pipeline includes FM13, AFM11, AFM21, AFM22, AFM24, TandAb and Trispecific Abs. It has started recruitment for Phase IIa clinical trial of AFM13 in patients with Hodgkin Lymphoma. It has initiated a Phase I clinical trial of AFM11 in patients with non-Hodgkin Lymphoma. AFM21 is in preclinical development. AFM22, which is an Epidermal Growth Factor Receptor variant III (EGFRvIII)/CD16A NK-cell TandAb is in preclinical development. AFM24 is an additional CD16A NK-cell TandAb targeting a validated solid tumor target, EGFR-wild type. It is developing Trispecific Abs for treating multiple myeloma, and CD33/CD3-specific T-cell TandAb to treat acute myeloid leukemia.

Receive News & Ratings for Molecular Templates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molecular Templates and related companies with's FREE daily email newsletter.

Leave a Reply